Trial Outcomes & Findings for Alefacept in Subjects With Chronic Plaque Psoriasis Who Failed to Respond to Anti-TNF Therapy (NCT NCT00953329)
NCT ID: NCT00953329
Last Updated: 2013-02-22
Results Overview
Terminated study
Recruitment status
TERMINATED
Study phase
PHASE4
Target enrollment
1 participants
Primary outcome timeframe
12 weeks (study terminated)
Results posted on
2013-02-22
Participant Flow
Recruitment ended in Dec 2008. Clinical Trial was located in Medical Center Clinic.
No adverse events occurred
Participant milestones
| Measure |
Alefacept Treated
|
|---|---|
|
Overall Study
STARTED
|
1
|
|
Overall Study
COMPLETED
|
0
|
|
Overall Study
NOT COMPLETED
|
1
|
Reasons for withdrawal
| Measure |
Alefacept Treated
|
|---|---|
|
Overall Study
Lack of Efficacy
|
1
|
Baseline Characteristics
Alefacept in Subjects With Chronic Plaque Psoriasis Who Failed to Respond to Anti-TNF Therapy
Baseline characteristics by cohort
| Measure |
Group 1
n=1 Participants
|
|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
1 Participants
n=5 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=5 Participants
|
|
Age Continuous
|
35 years
n=5 Participants
|
|
Sex: Female, Male
Female
|
1 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
1 participants
n=5 Participants
|
PRIMARY outcome
Timeframe: 12 weeks (study terminated)Population: Study terminated
Terminated study
Outcome measures
Outcome data not reported
Adverse Events
Group 1
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place